

*Amendments to the Claims:*

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.-65. (Cancelled)

66. (New) A method of treating or preventing a disorder of the eye comprising administering to the eye of an individual suffering from said disorder, a Neublabin polypeptide, which comprises an amino acid sequence that is at least 90% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 5, 6, 7, 9, 10, 11, 12, and 16.

67. (New) The method of claim 66, wherein the polypeptide comprises seven conserved cysteine residues at positions 8, 35, 39, 72, 73, 101, and 103 when numbered in accordance with SEQ ID NO. 2.

68. (New) The method of claim 66, wherein the polypeptide comprises amino acid residues as follows:

C at position 8, L at position 10, V at position 17, L at position 20, G at position 21, L at position 22, G at position 23, E at position 28, F at position 32, R at position 33, F at position 34, C at position 35, G at position 37, C at position 39, C at position 72, C at position 73, R at position 74, P at position 75, F at position 83, D at position 85, S at position 97, A at position 98, C at position 101 and C at position 103, each when numbered in accordance with SEQ ID NO. 2.

69. (New) The method of claim 66, wherein the polypeptide comprises an LGLG repeat, an FRFC motif, a QPCCR motif, and a SATACGC motif.

70. (New) The method of claim 66, wherein the disorder of the eye includes photoreceptor loss in the retina in patients afflicted with macular degeneration, retinitis pigmentosa, and glaucoma.

71. (New) The method of claim 66, wherein said Neublastin polypeptide comprises an amino acid sequence being at least 95% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 5, 6, 7, 9, 10, 11, 12, and 16.

72. (New) The method of claim 71, wherein said Neublastin polypeptide comprises an amino acid sequence being at least 95% homologous to any of SEQ ID NO 10, 11, and 12.

73. (New) A method of treating or preventing a disorder of the eye comprising administering to the eye of an individual suffering from said disorder, a virus vector comprising a polynucleotide encoding a Neublastin polypeptide, which comprises an amino acid sequence that is at least 90% homologous to an amino acid sequence selected from the group consisting of any one of the sequences set forth in SEQ ID NOs: 2, 4, 5, 6, 7, 9, 10, 11, 12, and 16.

74. (New) The method of claim 73, wherein the polypeptide comprises seven conserved cysteine residues at positions 8, 35, 39, 72, 73, 101, and 103 when numbered in accordance with SEQ ID NO. 2.

75. (New) The method of claim 73, wherein the polypeptide comprises amino acid residues as follows:

C at position 8, L at position 10, V at position 17, L at position 20, G at position 21, L at position 22, G at position 23, E at position 28, F at position 32, R at position 33, F at position 34, C at position 35, G at position 37, C at position 39, C at position 72, C at position 73, R at position 74, P at position 75, F at position 83, D at position 85, S at position 97, A at position 98, C at position 101 and C at position 103, each when numbered in accordance with SEQ ID NO. 2.

76. (New) The method of claim 73, wherein the polypeptide comprises an LGLG repeat, an FRFC motif, a QPCCRP motif, and a SATACGC motif.

77. (New) The method of claim 73, wherein the disorder of the eye includes photoreceptor loss in the retina in patients afflicted with macular degeneration, retinitis pigmentosa, and glaucoma.

78. (New) The method of claim 73, wherein said Neublastin polypeptide comprises an amino acid sequence being at least 95% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 5, 6, 7, 9, 10, 11, 12, and 16.

79. (New) The method of claim 78, wherein said Neublastin polypeptide comprises an amino acid sequence being at least 95% homologous to any of SEQ ID NO 10, 11, and 12.

80. (New) A method of treating or preventing a disorder of the eye comprising administering to the eye of an individual suffering from said disorder, a cell line expressing a Neublastin polypeptide, which comprises an amino acid sequence that is at least 90% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 5, 6, 7, 9, 10, 11, 12, and 16.

81. (New) The method of claim 80, wherein the polypeptide comprises seven conserved cysteine residues at positions 8, 35, 39, 72, 73, 101, and 103 when numbered in accordance with SEQ ID NO. 2.

82. (New) The method of claim 80, wherein the polypeptide comprises amino acid residues as follows:

C at position 8, L at position 10, V at position 17, L at position 20, G at position 21, L at position 22, G at position 23, E at position 28, F at position 32, R at position 33, F at position 34, C at position 35, G at position 37, C at position 39, C at position 72, C at position 73, R at position 74, P at position 75, F at position 83, D at position 85, S at position 97, A at position 98, C at position 101 and C at position 103, each when numbered in accordance with SEQ ID NO. 2.

83. (New) The method of claim 80, wherein the polypeptide comprises an LGLG repeat, an FRFC motif, a QPCCRP motif, and a SATACGC motif.

84. (New) The method of claim 80, wherein the disorder of the eye includes photoreceptor loss in the retina in patients afflicted with macular degeneration, retinitis pigmentosa, and glaucoma.

85. (New) The method of claim 80, wherein said Neublastin polypeptide comprises an amino acid sequence being at least 95% homologous to an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 5, 6, 7, 9, 10, 11, 12, and 16.

86. (New) The method of claim 85, wherein said Neublastin polypeptide comprises an amino acid sequence being at least 95% homologous to any of SEQ ID NO 10, 11, and 12.